‘Milestone’ treatment could reshape future leukaemia care
The Flair trial found that 94 per cent of patients who received the two targeted drugs were alive with no disease progression after five years
What's Your Reaction?
Like
0
Dislike
0
Love
0
Funny
0
Angry
0
Sad
0
Wow
0
